T2 Biosystems

T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish.
Type
Public
HQ
Lexington, US
Founded
2006
Employees
168 (est)+53%
T2 Biosystems was founded in 2006 and is headquartered in Lexington, US

Key People at T2 Biosystems

Glenn Magnuson

Glenn Magnuson

Vice President of Sales
Tom Lowery

Tom Lowery

Vice President of Diagnostics Research & Development
Sarah Kalil

Sarah Kalil

Chief Operating Officer
Marc Jones

Marc Jones

CFO
Rahul Dhanda

Rahul Dhanda

Vice President of Global Support Services Marketing
Michael Cima

Michael Cima

Co-Founder and Director

T2 Biosystems Locations

Lexington, US
Wilmington, US

T2 Biosystems Metrics

T2 Biosystems Summary

Market capitalization

$167 M

Closing share price

$5.4
T2 Biosystems's latest market capitalization is $167 M.

T2 Biosystems Market Value History

T2 Biosystems News

T2 Biosystems Company Life

You may also be interested in